Showing 2841-2850 of 5771 results for "".
- Atsena Granted FDA Regenerative Medicine Advanced Therapy Designation for Gene Therapy to Treat X-Linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-granted-fda-regenerative-medicine-advanced-therapy-designation-gene-therapy-to-treat-x-linked-retinoschisis/2482737/Atsena Therapeutics announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201, a gene therapy product candidate, leverages AAV.SPR, the company’s novel spreading capsid, to
- Biocon Biologics Secures Market Entry Date for Yesafili, Interchangeable Biosimilar to Eylea in the UShttps://modernod.com/news/biocon-biologics-secures-market-entry-date-for-yesafili-interchangeable-biosimilar-to-eylea-in-the-us/2482736/Biocon Biologics announced a settlement and license agreement with Regeneron that clears the way to commercialize Yesafili (aflibercept-jbvf), an interchangeable biosimilar aflibercept, in the United States. Yesafili, a vascular endothelial growth factor (VEGF) inhibitor, is used to tre
- Andrew Chang Joins BVI Medical as Chief Commercial Officerhttps://modernod.com/news/andrew-chang-joins-bvi-medical-as-chief-commercial-officer/2482735/BVI Medical announced the appointment of Andrew Chang to the newly created role of Chief Commercial Officer. Mr. Chang will lead the company’s global sales, global marketing, and commercial excellence teams and will report directly to President and CEO Shervin Korangy. Mr. Ch
- Tenpoint Therapeutics Submits NDA to FDA for Brimochol PF for the Treatment of Presbyopiahttps://modernod.com/news/tenpoint-therapeutics-submits-nda-to-fda-for-brimochol-pf-for-the-treatment-of-presbyopia/2482730/Tenpoint Therapeutics announced that the company has submitted a new drug application (NDA) to the FDA for Brimochol PF for the treatment of presbyopia. BRIMOCHOL PF combines brimonidine and carbachol in a pupil-modulating eye dro
- Nordic Pharma Receieves CE Mark Approval for Lacrifill Canalicular Gelhttps://modernod.com/news/nordic-pharma-receieves-ce-mark-approval-for-lacrifill-canalicular-gel/2482729/Nordic Group, the parent company of Nordic Pharma, announced that its dry eye therapy Lacrifill has received CE mark approval. This regulatory milestone, which Nordic says was achieved several months ahead of schedule, allows Nordic Pharma to introduce Lacrifill across Europea
- Orasis Launches Presbyopia Eyedrop Qlosi in the UShttps://modernod.com/news/orasis-launches-presbyopia-eyedrop-qlosi-in-the-us/2482728/Orasis Pharmaceuticals announced that Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, a novel, corrective prescription eye drop for the treatment of presbyopia in adults is now available to prescribe in the US. Qlosi’s proprietary 'EyeQ Formulation&
- Rayner Expands IOL Manufacturing Capacity to Meet Growing Demandhttps://modernod.com/news/rayner-expands-iol-manufacturing-capacity-to-meet-growing-demand/2482723/Rayner has completed a major expansion of its production facility in Worthing, UK, doubling its annual IOL manufacturing capacity to 4 million units, the company announced. Since opening its manufacturing pl
- Opthea Discontinues Wet AMD Trials After Another Failed Phase 3 Trialhttps://modernod.com/news/opthea-discontinues-wet-amd-trials-after-another-failed-phase-3-trial/2482721/Just a week after Opthea announced that its combination drug candidate—2 mg sozinibercept combined with 2 mg aflibercept—did not meet its primary endpoint in the COAST phase 3 trial, the company announced similar results with its phase 3 ShORe (Study of OPT-302 in
- Maura Sweeney Appointed Chief Operating Officer at Lighthouse Guildhttps://modernod.com/news/maura-sweeney-appointed-chief-operating-officer-at-lighthouse-guild-1/2482720/Lighthouse Guild announces the appointment of Maura Sweeney as Chief Operating Officer, effective April 1, 2025. Ms. Sweeney has been a vital part of Lighthouse Guild since 2010, most recently serving as Chief Program and Services Officer. A seasoned health care professional, she brings
- Alcon Acquires Majority Interest in Aurion Biotechhttps://modernod.com/news/alcon-acquires-majority-interest-in-aurion-biotech-to-advance-cell-therapy-for-corneal-endothelial-disease/2482718/Alcon announced it has acquired a majority interest in Aurion Biotech, a clinical-stage company developing cell therapies to treat eye diseases. Financial terms of the deal were not disclosed.